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Interferons (IFN) are essential antiviral cytokines that
establish the cellular antiviral state through upregu-
lation of hundreds of interferon-stimulated genes
(ISGs), most of which have uncharacterized func-
tions and mechanisms. We identified cholesterol-
25-hydroxylase (CH25H) as a broadly antiviral ISG.
CH25H converts cholesterol to a soluble antiviral
factor, 25-hydroxycholesterol (25HC). 25HC treat-
ment in cultured cells broadly inhibited growth of en-
veloped viruses including VSV, HSV, HIV, andMHV68
and acutely pathogenic EBOV, RVFV, RSSEV, and
Nipah viruses under BSL4 conditions. It suppressed
viral growth by blocking membrane fusion between
virus and cell. In animal models, Ch25h-deficient
mice weremore susceptible toMHV68 lytic infection.
Moreover, administration of 25HC in humanized
mice suppressed HIV replication and reversed T cell
depletion. Thus, our studies demonstrate a unique
mechanism by which IFN achieves its antiviral state
through the production of a natural oxysterol to
inhibit viral entry and implicate membrane-modifying
oxysterols as potential antiviral therapeutics.
INTRODUCTION
Viruses are obligate intracellular pathogens that—despite having
unique structures and functions—undergo lifecycle stages
of entry, transcription, translation, replication, assembly, and
egress. Upon binding to cell surface molecules, nonenveloped
viruses can enter the cell directly, whereas enveloped viruses
undergo a fusion process that requires specific interactions
between receptors and membranes on both the virus and the
cell. In the cellular cytoplasm or the nucleus, incipient viral92 Immunity 38, 92–105, January 24, 2013 ª2013 Elsevier Inc.proteins may be sufficient to initiate early lifecycle processes,
but full replication, transcription, and translation require utili-
zation of cellular factors. The newly synthesized viral proteins
and genome are coordinately assembled into virions, which
then exit the cell by lysis or budding.
Whereas viruses exploit host factors to successfully replicate,
the innate immune system inhibits viral growth by production of
interferons (IFN), which are essential antiviral cytokines that
induce a wide array of antiviral effectors. Many IFN-stimulated
genes (ISGs) work by inhibiting a specific viral lifecycle stage.
Interferon-induced transmembrane protein 3 (IFITM3) proteins
block viral entry, and ISG20, a 30-50 exonuclease, degrades
single-stranded viral RNA; PKR inhibits viral translation through
suppression of eIF2a elongation factors and tetherin prevents
release of virions from the cell (Garcı´a et al., 2006; Neil et al.,
2008; Van Damme et al., 2008; Brass et al., 2009; Degols
et al., 2007). These ISGs exemplify only a few of the hundreds
of confirmed ISGs; most of them are uncharacterized.
Cholesterol-25-hydroxylase (CH25H) is a conserved ISG,
which encodes an endoplasmic-reticulum-associated enzyme
that catalyzes oxidation of cholesterol to 25-hydroxycholesterol
(25HC) (Holmes et al., 2011). 25HC belongs to a diverse class
of endogenous oxysterols, the oxidation products of choles-
terol. It is widely understood to be a soluble factor that controls
sterol biosynthesis through regulation of sterol-responsive
element binding proteins (SREBP) and nuclear receptors (Kan-
dutsch et al., 1978; Janowski et al., 1999). Although oxysterols
have unique roles in metabolism, studies have implicated their
importance in immunity. Macrophages and dendritic cells
express CH25H in response to various toll-like receptor (TLR)
ligands and IFN (Bauman et al., 2009; Park and Scott, 2010).
Ch25h is a suppressor of immunoglobulin A (IgA) production
in B cells and may promote intracellular bacterial growth (Bau-
man et al., 2009; Zou et al., 2011). Dysregulation of 25HC is
associated with atherosclerosis, which is partly attributed to
its induction of the inflammatory cytokine, interleukin-8 (IL-8)
(Brown and Jessup, 1999; Wang et al., 2012). Although these
studies support a conserved immunological role of CH25H
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remain unclear.
We have found that CH25H is important for the host immune
response against viral infection. This study explores the antiviral
function of CH25H and the mechanism of its viral inhibition, as
well as its physiological significance during viral infections.
RESULTS
Ch25h Is an IFN-Dependent Gene with Antiviral Activity
In a microarray analysis of IFN-a- and IFN-g-stimulated murine
bone marrow-derived macrophages (BMMs), we found that
both types of IFNs induced expression of Ch25h within 3 hr
(Figure 1A; accession number GSE35825). Gene expression
analysis by qRT-PCR showed that Ch25h is induced by
polyI:C (TLR3 agonist) in bone-marrow-derived macrophages
(BMMs) and dendritic cells (BMDC) with higher induction in
response to IFN in BMMs (Figure 1B). In mice infected by
intraperitoneal (i.p.) injection with 5 3 106 plaque-forming units
(pfu) of VSV, Ch25h was induced after 18 and 36 hr in lung,
liver, and kidney, with highest induction in liver and kidneys
(Figure 1C). An RNA-seq analysis showed that toll-like
receptor 4 (TLR4) induction of Ch25h was dependent on IFN
receptor (IFNAR1) but independent of IL-27, a cytokine that
mediates IFN secondary gene expression, such as IL-10 (Fig-
ure 1D). This result was confirmed by qRT-PCR showing that
Ch25h expression was induced by TLR2, TLR3, TLR4, and
TLR9 agonists, with highest expression induced by polyI:C
(TLR3) and lipidA (TLR4). IFN receptor-deficient (Ifnar1/)
BMMs had abrogated Ch25h expression when treated with
these agonists showing that Ch25h expression is IFN-depen-
dent (Figure 1E).
In a previous study, we performed a blinded, unbiased
screen for antiviral ISGs against vesicular stomatitis virus
coexpressing GFP (VSV-GFP) (Liu et al., 2012). We cotrans-
fected individual plasmids encoding an ISG with a plasmid
encoding a red fluorescent protein, DsRed. Transfection pro-
ceeded for 36 hr before infection with VSV-GFP. At 9 hpi, we
quantified VSV-GFP with fluorescence-activated cell sorting
(FACS) by gating on DsRed-positive population, which are
cells that highly express the ISG (Figure 1F). Expression of
human CH25H inhibited VSV-GFP replication by 89% at
9 hpi (Figure 1G). IFN activators like TBK1, IFIH1, and IRF1
strongly inhibited VSV as well as the RNA exonuclease ISG20.
To validate the antiviral effect of CH25H, we generated a doxy-
cycline-inducible CH25H-flag construct coexpressing mCherry
(CH25H-mCherry). Doxycycline addition to HEK293T express-
ing this construct increased CH25H-mCherry expression (Fig-
ure 2A, top) and after infection, inhibited VSV-GFP expression
compared to vector control in a dose-dependent manner (Fig-
ure 2A, bottom). Taken together, CH25H overexpression is suffi-
cient to inhibit VSV growth.
Loss of Function of Ch25h Leads to Susceptibility
to Viral Infections In Vitro
We sought to determine whetherCh25hmight be a required anti-
viral factor. We generated Ch25h stable knockdown cell lines
from the murine macrophage cell line, RAW264.7, with two
distinct small hairpin RNA (shRNA) sequences against Ch25hand confirmed the knockdown by qRT-PCR (Figure 2B). Both
knockdown cell lines demonstrated increased VSV replication
compared to scramble control (Figure 2C). To further validate
these results, macrophage and B cell lines were generated
from Ch25h-deficient (Ch25h/) and matching wild-type (WT)
(Ch25h+/+) mice. In our conditions, we could not establish VSV
infection in primary cell lines; hence we immortalized BMMs
and B cells with J2 and BCR-ABL oncogenic retroviruses,
respectively. Ch25h/ J2 BMMs displayed 5-fold increased
susceptibility to VSV infection compared to Ch25h+/+ J2 BMMs
at 14 hpi. In B cells transformed with BCR-ABL, we observed
about 100-fold increase in VSV-GFP replication in three different
Ch25h/ B cell clones at 48 hpi compared to two Ch25h+/+
B cell clones (Figure 2E). These results show that Ch25h may
be required for host antiviral immunity.
CH25H Produces a Soluble Antiviral Factor
that Is Not IFN
In overexpression studies described in Figure 1, HEK293T were
transfected with ISG plasmids and DsRed in 3:1 ratio such that
DsRed-positive cells (DsRed+) should represent cells that highly
expressed the ISG, whereas DsRed-negative (DsRed-) cells
should represent low ISG expressers (Figure 3A). IFN activators,
TBK1, IFIH1, and IRF1, inhibited VSV-GFP expression in both
populations showing DsRed+ cells confer viral resistance to
DsRed- through a soluble factor, which is IFN (Figure 3B). In
contrast, the cytoplasmic viral RNA exonuclease, ISG20, only
inhibited VSV growth in DsRed+ population, but not DsRed
population. Overexpression of CH25H also inhibited virus in
both DsRed+ and DsRed populations suggesting that CH25H
produced a soluble factor that acts in trans to confer antiviral
activity onto other cells.
To determine whether CH25H produced a soluble antiviral
factor, we tested whether conditioned medium from cells over-
expressing CH25H had antiviral activity. HEK293T cells were
transfected with vector, interferon activators (TBK1, IFIH1, and
IRF1), CH25H, or ISG20, and the conditioned media was
transferred onto freshly plated HEK293T cells for 8 hr before
infection with VSV-GFP (0.01 MOI). As expected, conditioned
media from IFN activators inhibited VSV growth, but not
ISG20-conditioned medium (Figure 3C). Conditioned medium
from CH25H generated 60% VSV-GFP inhibition. We have
also observed similar effect in several human and murine cell
lines including HeLa, 3T3, BHK, Vero, MDCK, and Huh751 (see
Figure S1A available online). These results demonstrate that
CH25H produces a soluble antiviral factor.
IFN induces many ISGs that positively feed back and amplify
its production, leading to the hypothesis that the CH25H-
induced soluble factor is IFN. CH25H-conditioned medium,
however, had no detectable IFN-b by ELISA and did not
induce an IFN-stimulated responsive element (ISRE) luciferase
reporter (Figures S1B and S1C). More importantly, CH25H-
conditioned medium inhibited VSV replication in both Ifnar1/
fibroblasts and J2 BMMs. As negative controls, conditioned
media from IFN activators, IRF1, IFIH1, and RIG-I, were
unable to confer antiviral activity to Ifnar1/ cell lines (Figure 3E
and F). Taken together, CH25H produces a soluble factor that
is not IFN and can confer antiviral activity independent of
IFNAR1.Immunity 38, 92–105, January 24, 2013 ª2013 Elsevier Inc. 93
Figure 1. Ch25h Is an IFN-Dependent Antiviral ISG
(A) Gene expression profile of BMMs treated for 2.5 hr with IFN-a and IFN-g at 62 U/mL and 1 U/mL, respectively. IFN-a-stimulated genes that were 3-fold
higher than induction of IFN-g stimulated genes were categorized as IFN-a-specific (triangles) and vice versa for IFN-g-specific genes (squares). Ch25h is
denoted by asterisk (*).
(legend continued on next page)
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Has Antiviral Activity
CH25H catalyzes oxidation of cholesterol to 25-hydroxycholes-
terol (25HC), a soluble oxysterol that acts as an autocrine and
paracrine mediator (Figure 4A, top). We hypothesized that the
soluble antiviral factor generated by CH25H is 25HC. Treatment
of HEK293T cells with 25HC for 8 hr inhibited VSV-GFP ex-
pression in a dose-dependent manner with IC50 of 1 mM
(Figure 4A, bottom). Two other oxysterols, 22-(R)-hydroxycho-
lesterol (22R-HC) and 22-(S)-hydroxycholesterol (22S-HC), had
no effect on VSV. 22R-HC is also an agonist for the nuclear
hormone receptor liver X receptors (LXR), and 22S-HC is an
inactive ligand. Because 25HC has been implicated as a LXR
agonist, these results also suggest that the antiviral effect was
LXR independent. In addition, 25HC treatment of Ch25h+/+ and
Ch25h/ J2 BMMs reduced VSV replication (Figure 4B).
The effect of 25HC on cell viability and toxicity was also
assessed. 25HC treatment at ten times IC50 (10 mM) did not
increase LDH in supernatants of cells after 16 hr of treatment;
LDH level increased only after 30–40 hr treatment at 40 mM of
25HC (Figures S2A and S2B). Similarly, CH25H-conditioned
medium did not alter cell viability as measured by ATP levels
(Figure S2C). Therefore, CH25H carries out its antiviral effect
through its enzymatic product, 25HC.
CH25H and 25HC Are Broadly Antiviral
To determine the breadth of antiviral activity of CH25H, we
tested the effect of CH25H-conditioned medium and 25HC on
various viruses. For HIV, primary peripheral blood mononuclear
cells (PBMCs) were treated with conditioned medium or oxy-
sterol and subsequently infected with HIV NL4-3. At 3 dpi,
CH25H- and IRF1- conditioned media caused 75% reduction
of HIV NL4-3 p24 expression (Figure 4C). Similarly, 25HC
(1 mM) inhibited p24 expression by 80% at 3 dpi compared to
vehicle treatment, whereas 22S-HC had no effect (Figure 4D).
CH25H-conditioned medium also inhibited herpes simplex virus
1 (HSV-1) determined by plaque assay (Figure 4E), and expres-
sion of CH25H in HEK293T also reduced murine gammaherpes
virus (MHV68) infection by plaque assay (Figure 4F).
HIV, HSV-1, and MHV68 are viruses that achieve chronically
persistent infections. To determine whether 25HC can inhibit
acutely pathogenic viruses, we tested the effect of 25HC on
live Ebola virus (EBOV, strain Zaire), Nipah virus (NiV, strain
Bangladesh), Russian Spring-Summer Encephalitis virus
(RSSEV, strain Sofjin), and Rift Valley fever virus (RVFV,WT strain
ZH501 and vaccine strainMP12) under BSL4 conditions. Figures
4G–4J show that 1 mM of 25HC inhibited replication of these live
viruses. 25HC also inhibited replication of NiV and RVFV (MP12)(B) Ch25h expression was measured by qRT-PCR in BMMs and BMDCs after IF
(C) Ch25h expression quantified by qRT-PCR from tissues of uninfected (ui) and
(D) WT, Ifnar1–/-, and Il-27r/ BMMs were treated with lipid A (100 ng/mL) or
RKPM values.
(E) Ch25h gene expression measured by qRT-PCR of Ifnar1+/+ and Ifnar1/ BM
lipidA (10 ng/mL), and CpG-B (100 mM) for 4 hr. Mean ± SD.
(F) HEK293Twas cotransfected with fluorescent redmarker (DsRed) and with indi
with VSV-GFP (0.01MOI) for 9 hr. Representative contour plots are shown.
(G) As described in Part E, VSV-GFP was quantified in the DsRed-positive popula
percentage of GFP-positive and geometric mean of the fluorescence index (MFIin a dose-dependent manner (Figures S2D and S2E). In contrast,
25HC did not affect the growth of a GFP-expressing adenovirus,
which is a nonenveloped virus, measured by FACS (Figure 4K).
Taken together, CH25H and its cognate product, 25HC, exhibit
antiviral activity against several types of enveloped DNA and
RNA viruses, while having no effect on a nonenveloped virus.
25HC Inhibits VSV Entry
We took advantage of tools available for VSV and HIV to study
the mechanism of CH25H inhibition on the viral lifecycle. First,
we utilized the pseudotyped VSVDG-Luc reporter virus system
that has the receptor-binding G gene (VSV-G) replaced with
a luciferase reporter gene rendering it capable of only a single-
round of infection (Negrete et al., 2006). Quantification of lucif-
erase activity is indicative of viral lifecycle processes from entry
to protein synthesis. CH25H- and IRF1-conditioned media in-
hibited VSVDG-Luc expression suggesting inhibition of viral
replication at an early stage (Figure 5A). In a time-of-addition
experiment, longer pretreatment correlated with greater inhibi-
tion of VSVDG-Luc expression, compared to vehicle treated
controls (Figure 5B). These results suggest that 25HC does not
inhibit VSV during infection or after infection has taken place.
Rather, it is likely that 25HC establishes an antiviral state prior
to infection.
Because these data implicate early viral steps in the viral life-
cycle may be affected, we carried out experiments to determine
whether 25HC affects attachment. HEK293Ts were treated for
8 hr with ethanol vehicle control (EtOH), 25HC (1 mM), and CPZ
(10 mg/mL), an endocytosis inhibitor that would have no effect
on binding. To measure binding, VSV (5MOI) was incubated
with HEK293T at 4C for 1 hr to allow for binding but not cell
entry. After washing three times with cold PBS, quantification
of VSV genomic RNA (gRNA) showed no statistical difference
between 25HC and controls (Figure 5C).
To determine whether 25HC affects efficiency of fusion, we
established a VSV-G b-lactamase (bla) entry assay based on
the ability of VSV-G to be pseudotyped onto viral-like particles
made from the bla-Nipah virusmatrix fusion protein, herein called
VSV-G-blaM (Wolf et al., 2009). VSV-G mediated fusion will
result in cytoplasmic delivery of blaM; by addition of lipophilic
fluorescent CCF2-AM substrate, the bla activity can be mea-
sured by the green (525 nm) to blue (485 nm) fluorescence shift
as a result of CCF2-AM cleavage (Zlokarnik et al., 1998). Hence,
efficiency of virus-cell fusion can be measured by the increase in
the ratio of blue to green (blue:green) fluorescence, which is
reflective of the bla activity associated with blaM that has been
released into the cytoplasm after VSV-G mediated fusion (Cav-
rois et al., 2002; Wolf et al., 2009). Unlike the VSVDG-LucN (2,000 U/mL) or polyI:C (1 ug/mL) treatment for 4 hr.
VSV-infected C57B/6 mice collected at indicated times.
saline control for 4 hr and 12 hr. Ch25h expression values are presented as
Ms stimulated with TLR agonists, Pam-3-Cys (100 ng/mL), polyI:C (25 ug/mL),
vidual plasmids encoding human vector,CH25H, or TBK1 for 36 hr and infected
tion normalized to vector control. VSV-GFP was defined as the product of the
). Mean ± SEM; *p < 0.001.
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Figure 2. Ch25h-Deficiency Increases Susceptibility to Viral Infection In Vitro
(A) HEK293T was transfected with doxycycline-inducible vector orCH25H-flag constructs that coexpress red fluorescent mCherry for 24 hr and doxycycline was
added for 12 hr at indicated concentrations. Expression of CH25H-flag was confirmed by protein immunoblot (upper panel). After treatment, cells were infected
with VSV-GFP (0.01MOI) for 9 hr and VSV-GFPwas quantified by (percentage of GFP+ XGeoMeanMFI). Dots represent the percentage of mCherry-positive cells
(lower panel).
(B) RAW264.7 stably knocked down with shRNA against Ch25h were generated by retro-viral infection. Two shRNA constructs were made (shCh25h-A and
shCh25h-B) along with scramble control. Knockdown was confirmed by qRT-PCR. Mean ± SD, *p < 0.01.
(C) shCh25h-A, shCh25hB, and scrambled stable RAW264.7 were infected with VSV-GFP (0.1 MOI) and the VSV-GFP was measured by plaque assay at 14 hpi.
Mean ± SEM, *p < 0.01.
(D) J2 BMMSwere derived from Ch25h+/+ andCh25h/mice and passed for 2 weeks. The cells were infected with VSV-GFP (0.1 MOI) and viral titers at 14 hpi in
the supernatants were quantified by plaque assay. Mean ± SD. *p < 0.01.
(E) Individual clonal populations of BCR-ABL transformed B cells fromCh25h+/+ andCh25h/mice were infected with VSV-GFP (0.1MOI) in biological triplicates
and the viral titers were measured by plaque assay at indicated times. Mean ± SD. *p < 0.01.
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require transcription and translation of viral proteins for detec-
tion. Fusion is proportional to blaM concentration, which is esti-
mated by the rate constant (k) derived from the slope of the reac-
tion during the linear phase of the reaction within the first hour.
We first demonstrated that IFN treatment of HEK293Ts could
cause a dose-dependent inhibition of viral entry by VSV-G-blaM
assay (Figure 5D), suggesting that there exist ISGs that block
viral entry. To test whether CH25Hmay partlymediate this effect,
HEK293Ts were transfected with several ISGs for 48 hr and in-
fected with VSV-G-blaM. Figure 5E showed that CH25H expres-96 Immunity 38, 92–105, January 24, 2013 ª2013 Elsevier Inc.sion reduced efficiency of VSV-G-mediated fusion. Compared
to vector control, blaM activity from CH25H-transfected cells
proceeded at 48% of vector-transfected cells (compare rate
constants in Figure 5E, inset table) and reached a plateau level.
The previously described entry inhibitor, IFITM3, also reduced
VSV-G mediated fusion (Brass et al., 2009). Expression of
ISG20, a viral RNA exonuclease, had no effect on viral entry.
IRF1-transfected cells also inhibited fusion, presumably by
upregulation of IFN. CH25H-conditioned medium similarly in-
hibited VSV-G-blaM fusion, with a more pronounced effect
than IRF1-conditioned medium (Figure 5F). Furthermore,
Figure 3. CH25H Produces a Soluble Antiviral Factor That Is Not IFN; See Also Figure S1
(A) HEK293Ts were cotransfected with ISGs and DsRed as Figure 1D. Schematic of FACS analyses of VSV-GFP in total, DsRed+, and DsRed populations.
VSV-GFP was defined as percentage of GFP+ X geometric MFI.
(B) HEK293T transfected with DsRed and indicated expression plasmids were infected with VSV-GFP and measured as described in Figure 3A. Mean ± SEM.
(C) Media collected from HEK293T after 48 hr transfection with indicated expression vector was treated on to freshly plated HEK293T for 8 hr and infected with
VSV-GFP (0.01 MOI) for 9 hr. VSV-GFP was quantified as described in Figure 3A. Representative histogram of FACS data (right). Mean ± SEM, *p < 0.01.
(D) Ifnar1/ tail-derived fibroblasts were treated for 12 hr with conditioned-medium of HEK293T cells transfected with indicated expression vector. The
fibroblasts were infected with VSV-GFP (0.1 MOI) and the viral titer in the supernatant was measured by plaque assay. Mean ± SEM, *p < 0.05.
(E) Ifnar1/ derived J2 BMMs were treated for 12 hr with conditioned-medium of HEK293T cells transfected with indicated expression vector. J2 BMMs were
infected with VSV-GFP (0.1 MOI) and the viral titer in the supernatant at 14 hpi was quantified by plaque assay. Mean ± SEM, *p < 0.05.
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fusion, by 44%, 56%, and 70%, respectively (Figure 5G). These
results demonstrate that CH25H, and its cognate product,
25HC, inhibits efficiency of virus-cell fusion.
To delineate whether 25HC affects viral or cellular mem-
brane, we tested how infectivity of the virions was affected
when produced from 25HC-treated cells. HEK293T cells were
treated with and without 25HC (2.5 mM) for 8 hr and infected
with live VSV at 0.01 MOI for 1 hr. Viral supernatants were puri-
fied and cleared of residual 25HC by ultracentrifugation through
a 20% sucrose cushion. As expected, there was >60% reduc-
tion in the amount of VSV from 25HC treated samples versus
control, as measured by qRT-PCR for the number of viral
genome copies (gRNA) (Figure S3A). To assess infectivity, we
normalized viral titer from 25HC- or vehicle-treated cells basedon gRNA. After normalization, VSV titer from 25HC-treated cells
was equivalent to the titer from vehicle-treated cells determined
by plaque assay (Figure S3B). These results show that 25HC
does not affect viral infectivity but instead affects the cellular
membrane property.
25HC is a suppressor of SREBP2, a factor that controls sterol
biosynthesis. We hypothesized that suppression of SREBP2 by
25HC can inhibit viral growth and tested whether active (cleaved)
forms of SREBPs in HEK293T would overcome 25HC’s anti-viral
effect. Overexpression of active forms of Srebp1a, Srebp1-c,
and Srebp2 in HEK293Ts, however, did not reverse 25HC’s anti-
viral effect (Figure S3C). 25HC also suppresses many sterol
biosynthetic enzymes including HMG-coenzyme A (CoA) reduc-
tase, which produces the key intermediate mevalonate (Pezacki
et al., 2009) (Figure S3D). We hypothesized that mevalonate mayImmunity 38, 92–105, January 24, 2013 ª2013 Elsevier Inc. 97
Figure 4. CH25H Produces 25-Hydroxycholesterol, a Broadly Antiviral Oxysterol; See Also Figure S2
(A) CH25H converts cholesterol to 25HC (top). HEK293T was treated with 22(S)-, 22(R)-, or 25- hydroxycholesterol and the vehicle, ethanol (EtOH) for 8 hr with
indicated concentrations and infected with VSV-GFP. VSV-GFP was quantified at 8 hpi as described in Figure 3A. Mean ± SEM.
(B) Ch25h+/+ andCh25h/ J2 BMMswere treated with 25HC (1 mM) or EtOH and infected with VSV-GFP (0.01 MOI). VSV-GFPwas quantified by FACS at 12 hpi.
Mean ± SD; *p < 0.02.
(C) Costimulated PBMC were preincubated for 24 hr in conditioned media before infection with HIV NL4-3. At 3 dpi, p24 in triplicate samples were quantified
by ELISA. Mean ± SEM; *p < 0.001.
(D) Costimulated PBMC were preincubated for 24 hr in 22(S)-HC (1 mM), 25HC (1 mM), and vehicle (EtOH) containing media before infection with HIV NL4-3 in
triplicates. At 3 dpi, p24 was quantified by ELISA. Mean ± SEM; *p < 0.001.
(E) HEK293T was treated with indicated conditioned media for 12 hr and infected with HSV (0.25 MOI) for 24 hr. HSV titer in the supernatant was quantified by
plaque assay. Mean ± SEM; *p < 0.001.
(legend continued on next page)
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CH25H Inhibits Viral Growth by Production of 25HCreverse the antiviral effect of 25HC. Addition of exogenous me-
valonate (300 mM) to HEK293T before and during 25HC treat-
ment, however, did not reverse the antiviral effect of 25HC
(Figure S3E).
25HC alsomay inhibit production of another biosynthetic inter-
mediate isopentenyl-pyrophosphate (Isopentyl-PP), which is
substrate for prenylationof proteinsmediatedby farnesyltransfer-
ase (FTase) andgeranylgeranyltransferase (GTase).We tested the
hypothesis that inhibition of prenylation can inhibit VSV growth.
HEK293T were treated with FTase and GTase inhibitors, FTI-
276 and GGTI-298 (5–20 mM), and infected with VSV-GFP. FTI-
276 treatment had no effect on VSV, whereas GGTI-298 reduced
viral growth at 10–20 mM (Figure S3F). GGTI-298, however,
caused >10% reduction in cell viability by ATP content, whereas
25HC and FTI had no effect (Figure S3G). Furthermore, FTI-276
and GGTI-298 did not reduce VSV fusion by VSV-G-blaM assay
(Figures S3H and S3I). Taken together, although prenylation
inhibition may have some antiviral effect, it may decrease cell
viability and does not affect viral entry as seen with 25HC.
CH25H and 25HC Inhibits HIV Entry
We sought to validate CH25H and 25HC antiviral mechanism on
HIV, a virus that undergoes pH-independent entry. In CEM cells,
25HC inhibited >50% luciferase expression from single round
infection of pseudotyped HIV-IIIB coexpressing luciferase (Fig-
ure 6A). AZT, an inhibitor of reverse transcription that served
as positive control, inhibited the expression by 70%. Hence,
25HC inhibits HIV lifecycle prior to or at protein translation.
HIV initiates reverse transcription of its genomic RNA to DNA
immediately after entry. We examined the effect of 25HC on
the production of full-length, reverse-transcribed DNA (lateRT).
CEM cells were infected with pseudotyped HIV-IIIB and lateRT
was measured by qRT-PCR. 25HC inhibited lateRT expression
70% at 6 hpi (Figure 6B). AMD3100, a HIV entry inhibitor,
served as positive control and Elvitegravir, an inhibitor of
DNA integration, was used as a negative control. Hence, 25HC
inhibits HIV life cycle before reverse transcription.
We next tested whether CH25H inhibits HIV growth at the
level of entry. We coexpressed pNL4-3 with bla-VPR fusion
gene to produce virions containing bla-VPR (NL4-3-bla). CEM
cells treated with CH25H-conditioned medium exhibited 65%
reduction in viral entry compared to vector- and ISG20-condi-
tioned media. AMD3100 abrogated NL4-3-bla entry (Figure 6C).
We further confirmed our findings by FACS analysis and
observed 50% decrease in the number of cells expressing
cleaved CCF2-AM substrate (blue population) in CEM cells(F) HEK293Ts were transfected with indicated expression plasmids and infected w
plaque assay. Mean ± SEM; *p < 0.001.
(G) HeLa cells were pretreated with 25HC (1 mM) or EtOH containingmedia for 5 hr
supernatants from biological triplicates were combined and measured by plaque
(H) HeLa cells were pretreated with media containing indicated concentrations o
time points, supernatants from biological triplicates were combined and measur
(I) HeLa cells were pretreated as in Figure 4H and infected with RSSEV at 0.1
combined and measured by plaque assay.
(J) HeLa cells were pretreated with media containing indicated concentrations of 2
at 0.1 MOI. Viral titer at indicated time points was measured by plaque assay. V
(K) HEK293Twere treated with EtOH, 22S-HC, and 25HC for 12 hr and infected wi
X Geometric MFI). Mean ± SEM; *p < 0.001.treated with CH25H-conditioned medium compared to control
(Figure S4A). Treatment of CEM cells with 25HC (5 mM) for
24 hr caused 88% decrease in NL4-3-bla blue-green ratio at
the endpoint, normalized to AMD3100 positive control as 100%
inhibition (Figure 6D). Similarly, there was 87% reduction in
cells expressing cleavedCCF2-AMby FACSanalysis (Figure 6E).
Because 25HC may have diverse cellular effects, we asked
whether 25HCmight affect other HIV life cycle stages. To assess
its effect on HIV transcription, HEK293Ts were transfected with
pNL4-3 coexpressing GFP (NL4-3-GFP) and treated with 25HC
4 hr post transfection. NL4-3-GFP expression determined by
FACS after 24 hr was not suppressed, suggesting that 25HC
did not affect HIV transcription and translation (Figure S4B).
Concurrently, treatment with 25HC did not reduce budding of
HIV virions from NL4-3-GFP transfected cells as measured by
p24 in the supernatants, whereas Nelfinavir, an HIV protease
inhibitor that reduces subsequent budding, inhibited p24
expression by >50% at 24 and 48 hr post transfection (Fig-
ure S4C). Taken together, CH25H and 25HC inhibits the effi-
ciency of HIV entry, however, does not affect HIV transcription,
translation, and budding processes.
25HC Inhibits Viral Protein-Mediated Cell-Cell
Membrane Fusion
Although the blaM entry assays demonstrated that 25HC inhibits
viral entry processes up to fusion, we sought to test whether
25HC actually inhibits the viral-mediated membrane fusion.
Because 25HC inhibited live Nipah replication (Figure 4H),
we took advantage of the robust system of NiV fusion (F) and
attachment (G) proteins to induce pH-independent cell-cell
membrane fusion to form syncytias. Vero cells were transfected
with recombinant NiV F and G at equal ratios for 5 hr and
refreshed with media containing 25HC or vehicle control. At
21 hr post transfection, cells were fixed and stained by Giemsa.
Grossly, 25HC treatment led to less syncytia formation and
fewer nuclei per syncytia compared to control (Figure 6F). In
a blinded count of numbers of nuclei per syncytia, a standard
measure of fusion, 2 mM of 25HC reduced fusion by 50% and
10 mM by 60% relative to control (Figure 6G). These data
demonstrate that 25HCmodifies the cellular membrane to inhibit
viral membrane fusion.
25HC Directly Modifies Cell Membrane to Impede Viral
Infection
We further explored whether 25HC can directly change mem-
brane property to inhibit fusion. We hypothesized that artificialith MHV68 (0.2MOI) for 24 hr. MHV68 titer in the supernatant was quantified by
and infected with Ebola Zaire-GFP (EBOV) at 0.1MOI. At indicated time points,
assay.
f 25HC or EtOH for 18 hr and infected with Nipah virus at 0.1 MOI. At indicated
ed by plaque assay.
MOI. At indicated time points, supernatants from biological triplicates were
5HC or EtOH for 5 hr and infected withWT Rift Valley Fever Virus ZH501 (RVFV)
alues represent means of samples from triplicates.
th adenovirus-GFP and VSV-GFP and quantified by FACS (percentage of GFP+
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Figure 5. 25HC Inhibits VSV Entry; See Also Figure S3
(A) HEK293Ts were treated with conditioned media for 12 hr and infected with VSV-G pseudovirus encoding VSVDG luciferase (VSVDG-Luc-G). The cell lysates
were collected at indicated times and measured for luciferase activity. Mean ± SEM, *p < 0.001.
(B) HEK293T were treated with 25HC (5 mM) at different times relative to the VSVDG-Luc-G infection. For time 0, VSVDG-Luc-G and 25HC were added together
to the cells for 1 hr. Negative numbers on the x axis indicate addition of 25HC before infection; positive number indicates addition after infection. Relative light
units (RLU) is represented as mean ± SD. *p < 0.01.
(C) HEK293T were treated with respective agonists for 8 hr in triplicates. Under 4C conditions, VSV was bound to cells, washed three times with PBS, and
incubated for 30 min before total RNA collection. VSV genomic RNA was quantified by qRT-PCR mean ± SEM; *p < 0.05.
(D) HEK293T were treated with pan-IFN for 12 hr at indicated concentrations and infected with VSV-G-blaM in triplicates. blaM activity was measured by
CCF2-AM cleavage. Mean ± SEM, *p < 0.05, **p < 0.01.
(E) HEK293Twas transfected with indicated expression plasmids for 24 hr and infectedwith pseudovirus with encoding NipahM-b-lactamase inside VSV-G (VSV-
G-blaM) for 1.5 hr. bla activitywasmeasuredby blue:green ratio of the cleavedCCF2-AM.Relative fusionwasmeasuredby rate constant (k) (table, inset) estimated
from the slope of the linear phase reaction (bracketed time interval). Calculated k is represented the percentage of vector control, set to 100%. *p < 0.05, **p < 0.01.
(F) HEK293T was treated with indicated conditioned media for 12 hr and infected with VSV-G-blaM. Analysis was same as (D). *p < 0.05, **p < 0.01.
(G) HEK293T was treated with indicated concentration of 22(S)-HC, 25HC, and equivalent volume of vehicle (EtOH) for 12 hr and infected with VSV-G-blaM.
Analysis was same as (D). *p < 0.05, **p < 0.01.
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CH25H Inhibits Viral Growth by Production of 25HCliposomes with 7:3 phosphatidylcholine:cholesterol ratio, which
is similar to the composition of cell membranes, would compete
with the ability for 25HC to incorporate into cell membrane.
Although liposome treatment alone had no effect on viral infec-
tion in HEK293T, they caused a dose-dependent reversal of
VSV growth inhibition by 25HC (Figure 6H). As a positive control,
we demonstrated that liposome could compete with a known100 Immunity 38, 92–105, January 24, 2013 ª2013 Elsevier Inc.viral membrane fusion inhibitor, LJ001, as described previously
(Wolf et al., 2010). These results show that 25HC directly
modifies cellular membrane to inhibit viral fusion.
25HC Reduces HIV Infection In Vivo
We used HIV infection in a humanized mouse model to
determine the antiviral effect of 25HC in vivo. Humanized
Figure 6. 25HC Inhibits HIV Entry and Viral-Cellular Membrane Fusion; see also Figure S4
(A) CEM cells were treated with vehicle (EtOH), 22S-HC (5 mM), AZT (10 mM), 25HC (1 mM and 5 mM) for 12 hr and underwent single-round infection with HIV-IIIB
coexpressing luciferase. Cell lysates were collected after 24 hr and measured for luciferase activity. RLU is represented as mean ± SD. *p < 0.05.
(legend continued on next page)
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CH25H Inhibits Viral Growth by Production of 25HCNOD-Rag1nullIl2rgnull mice (NRG-hu) were administered 25HC
(50 mg/kg) 12 hr prior to infection with HIV NL4-R3A by i.p. injec-
tion. 25HC or the vehicle, 2-hydroxypropyl-b-cyclodextrin
(HbCD), was administered daily and the serum was collected 7
dpi. Quantification of HIV RNA in the serum from two combined
experiments showed >80% reduction of HIV RNA (copies/mL) in
25HC-treated mice compared to vehicle-treated mice (p <
0.0001) (Figure 7A). At termination of the experiment on 14 dpi,
the percent of HIV p24+ CD4 T cells from spleens of 25HC-
treated mice was significantly lower than that of controls (Fig-
ure 7B). Moreover, at 10 dpi, 25HC prevented HIV-mediated
CD4+ T cell depletion compared to vehicle control in CD3+(live
T cell) population in peripheral blood leukocytes (p < 0.05); this
effect was less significant in the spleen (p = 0.06) (Figure 7C).
These data show that administration of 25HC has antiviral effect
against HIV in vivo.
Ch25h-Deficient Mice Are More Susceptible to Viral
Infections
To determine whether Ch25h has a physiological role in host
defense against viral infection, we tested whether Ch25h/
mice had increased susceptibility to infection when compared
to matching WT mice (Ch25h+/+). Because Ch25h expression
inhibited MHV68 in vitro, we used MHV68 coexpressing lucif-
erase (MHV68-Luc) to infect mice so that viral lytic growth
kinetics could be measured in real time by bioluminescence.
Eight-week old female Ch25h+/+ and Ch25h/ mice (n = 4 in
each group) were infected with 500 pfu of MHV68-Luc i.p. and
imaged every day after 3 dpi. Average and maximal lumines-
cence intensities from ventral, right, left, and dorsal side of
every mouse were measured. We observed significantly higher
MHV68-Luc activity in Ch25h/mice over Ch25h+/+ mice start-
ing 5 dpi and maximal differences between day 7 and 8 (Figures
7D and 7E). MHV68-Luc activity began to wane in both groups
by 9 dpi, albeit at a slower rate in Ch25h/ mice. In support
of the imaging results, Ch25h/ spleens had approximately
3.5-fold higher MHV68 genomic DNA than spleens of
Ch25h+/+ mice at 10 dpi (Figures 7F and 7G). These results
show that Ch25h is a physiologically important antiviral factor.
DISCUSSION
We have identified the antiviral activity of an IFN-inducible gene,
CH25H, through a systematic, functional screen. Distinct from
known IFN-mediated antiviral mechanisms, CH25H inhibits
growth of a wide range of enveloped viruses by production of(B) CEM cells were treated with elvitegravir (10 mM), AMD3100 (10 mM), 25HC (1 mM
HIV full-length late reverse transcript (LateRT) was quantified by qRT-PCR with T
(C) CEM cells were treated with indicated conditionedmedia or AMD3100 for 8 hr
activity was measured by cleavage of CCF2-AM by fluorescence plate reader. M
(D) Similar to (C). CEM cells were treated with indicated 25HC (5 mM) and vehicle
(E) After kinetic assay in Figure 6D, percentage of cleaved CCF2-AM (blue) popu
(F) Vero cells were transfected with Nipah F and G receptors. Five hr after transfec
after transfection and Giemsa stained. Images were taken under light microscop
(G) Syncytias were defined by the presence of four or more nuclei in a common
nuclei per syncytia under the experimental conditions to the vehicle (ethanol) tre
(H) HEK293T was incubated with 25HC (1 mM) and varying concentrations of PC:
control, VSV-GFP was treated with LJ001, a known entry inhibitor, for 10 min prio
VSV-GFP was quantified by FACS as described in Figure 3A; mean ± SEM.
102 Immunity 38, 92–105, January 24, 2013 ª2013 Elsevier Inc.a soluble oxysterol, 25-hydroxycholesterol. It is also an ISG
that produces a soluble antiviral factor that is not IFN itself.
Independent of its known regulatory effect on metabolism,
25HC impairs viral entry at the virus-cell fusion step by inducing
cellular membrane changes. In animal models, administration of
25HC reduces HIV infection in humanized mice. Moreover, the
immune response against viral infections requires Ch25h in vivo.
These findings illustrate an essential function of CH25H in
immunity.
This study shows an unappreciated relationship between the
host IFN response and an oxysterol. Although antiviral effects
of some oxysterols have been documented (Moog et al., 1998;
Pezacki et al., 2009), we have found that 25HC broadly inhibits
viral membrane fusion, which is not specific to particular struc-
tural class of fusion proteins. For example, HIV and Ebola have
class-I fusion peptides and RVFV and RSSEV use class-II
peptides, whereas VSV and HSV belong to class III (Kielian and
Rey, 2006; Vaney and Rey, 2011). 25HC is also antiviral against
viruses that undergo either pH-dependent or pH-independent
fusion as typified by VSV and HIV, respectively. These findings
suggest that 25HC affects a more basic fusion process involving
the viral and cellular membrane.
Because 25HC can permeate through membranes, it likely
modifies cellular membranes to exert its antiviral effect. Our
study showed that artificial liposomes similar to cell membranes
reduce antiviral activity of 25HC, suggesting that they take up
25HC. In support of this finding, prior studies have shown that
25HC increased cellular cholesterol accessibility by directly
mobilizing cholesterol from membranes and prevented choles-
terol’s condensing effects on membrane (Lange et al., 1995;
Olsen et al., 2011). In artificial membranes, 25HC altered solvent
exposure of phospholipid head groups (Gale et al., 2009). One
model suggested that while membrane cholesterol orients in
parallel to adjacent acyl chains, 25HC adopts a tilted position
in the membrane because of its hydroxyl group and may
lead to membrane expansion. We also propose the possibility
that the hydrophilic interactions of the hydroxyl groups of
25HC can lead to aggregation in themembrane. These perturba-
tions could affect virus-cell fusion, which is fundamentally
dependent on membrane properties such as spacing of lipid
head groups, receptor accessibility, membrane curvature, and
fluidity (Pe´cheur et al., 1999; Teissier and Pe´cheur, 2007).
Studies on viral entry have predominantly focused on viral fusion
components and their interactions with specific cellular recep-
tors. How membrane properties modulate viral fusion remains
the subject of further research.), and vehicle (EtOH) for 12 hr and infected with HIV III-B pseudovirus. At 6 hpi,
aqman probe and normalized to mitochondrial DNA. Mean ± SD, p% 0.05.
and infected with HIV NL4-3 encoding Vpr-blaM (NL4-3/blaM) in duplicates. bla
ean ± SD, *p% 0.01.
(EtOH) for 12 hr and infected with HIV NL4-3/blaM.
lation (485 nm) was confirmed by FACS.
tion, the cells were treated with indicated conditions. The cells were fixed 21 hr
y.
cell membrane. Relative fusion was determined by normalizing the number of
ated group, set to 100%. Mean ± SEM, p < 0.0001.
cholesterol (7:3) liposomes for 8 hr before infection with VSV-GFP. As positive
r to infection (Wolf et al., 2009) (see Supplemental Experimental Procedures).
Figure 7. 25HC Inhibits HIV Replication and Ch25h Is Required for Antiviral Immunity In Vivo
(A) 25HC (50 mg/kg) or vehicle (HbCD) was administered 12 hr before HIV NL4-3 infection in humanized mice (NRG-hu). Treatment was administered daily after
infection. Viral titer in serum was measured by qRT-PCR 7 dpi. Results are combined from two experiments. ***p < 0.001.
(B) Spleens from NRG-hu mice were harvested 14 dpi and quantified by FACS after HIV p24 intracellular staining. *p < 0.05.
(C) Percent of CD4+ T cells was compared by FACS in 25HC- and EtOH-treated group. Representative FACS plots are shown (right). *p < 0.05.
(D) Ch25h+/+ and Ch25h/ mice were infected with MHV68-Luc (500 pfu) and the amount of infection was quantified everyday by bioluminescence imaging.
Average intensities (photons/sec/cm2/steradian) from ventral, right, left, and dorsal sides were measured for all mice. Mean ± SEM, *p < 0.05 by student’s t test at
indicated time point.
(legend continued on next page)
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bition by CH25H and 25HC under the experimental conditions as
described, which are generally 8–16 hr pretreatment with 1–
10 mMof 25HC in standard growthmedium. Given the expanding
role of oxysterol functions, other antiviral mechanisms may exist
and manifest with different conditions or viruses. Of note, over-
expression of CH25H caused more pronounced inhibition of
live VSV-GFP replication than VSV-G-blaM fusion, about
85% and 51%, respectively. However, in CH25H-condi-
tioned-medium- or 25HC- treated cells, the reduction was
comparable between VSV replication and VSV fusion,, ranging
about 55%–70%. One interpretation is that the CH25H protein
may have additional antiviral mechanisms to 25HC, perhaps
through its association with the endoplasmic reticulum. These
results encourage further study into other antiviral mechanisms
of CH25H and 25HC.
This study provides further understanding to the intricate
connection of IFN and metabolism. Although 25HC has been
associated with pathological conditions like atherosclerosis
and Alzheimer’s disease, our study shows that it plays a benefi-
cial role in host immunity against viral infections. These results
encourage the exploration of antiviral oxysterols or cellular
membrane modifiers as viral entry inhibitors.
EXPERIMENTAL PROCEDURES
Cell and Reagents are detailed in Supplemental Experimental Procedures.
VSV, HSV, MHV68, HIV Viral Infection
HEK293T and RAW264.7were infectedwith VSV-GFP at 0.01MOI for 1 hr, and
the media was changed with fresh media. For J2 BMMs and BCR-ABL B cells,
1MOI VSV-GFP was used. Approximately 150 mL of supernatants were
collected at various times between 8 and 16 hpi for plaque assay. For HSV
and MHV68, 0.25 MOI was used for infection and supernatants were collected
at 24 hpi. Titers were measured by standard plaque assays. Detail conditions
and HIV infection in hPBMCs are described in Supplemental Experimental
Procedures.
Ebola, RSSEV, Nipah, and RVFV Infections
HeLa cells were pretreated with 25HC (1 mM) or EtOH containing medium
for indicated times prior to infection with 0.1 MOI of Ebola-Zaire-GFP
(EBOV) or RVFV (WT strain ZH501 or vaccine strain MP12), Nipah virus
(Bangladesh), or RSSEV (Sofjin). Cell culture supernatant pooled from bio-
logical triplicates at indicated time points, prior virus titration by plaque
assay. Titers were measured by standard plaque assays (Supplemental
Experimental Procedures).
VSV-G-blaM Infection
VSV-G-blaM was produced as previously described and detailed in Supple-
mental Experimental Procedures (Wolf et al., 2009). HEK293Ts were treated
with 25HC and EtOH as before and infected with VSV-G-blaM at the empiri-
cally determined concentration for 1 hr. Cells were washed and CCF2-AM
was added according to manufacturer’s protocol (Invitrogen).
NL4-3 VPR-blaM Infection of CEM Cells
CEMs cells were treated with 25HC or EtOH for a minimum of six hours and
AMD3100 (20 mM) for 15 min before infection with concentrated NL4-3 blaM
or bald virus. Infections were spin inoculated for 60 min at 2,000 RPM, and(E) Similar to Figure 7D, maximum intensities (photons/sec/cm2/steradian) were
(F) MHV68 genomic DNA from Ch25h+/+ and Ch25h/ infected mice 9 dpi was
*p < 0.01.
(G) Bioluminescent images of Ch25h+/+ and Ch25h/ mice at 9 dpi.
104 Immunity 38, 92–105, January 24, 2013 ª2013 Elsevier Inc.incubated for 2 hr at 37C. After washing, CCF2-AM (Invitrogen) was added
according to manufacturer’s protocol. Kinetic readings were taken for 4 hr.
After the kinetic reading, the cells were washed with FACS Buffer, fixed with
2% paraformaldehyde, and examined by FACS. Data was analyzed using
FlowJo (Tree Star Inc.).
Nipah Fusion Assay and Liposome Competition Assay
Vero cells were plated in 6-well dish at 5 3 105 per well overnight and trans-
fected with 0.5 mg of expression plasmids encoding Nipah F andG in OptiMEM
(Invitrogen). At 5 hr post transfection, media was changed to DMEM (10%
FBS) with or without 25HC. The cells were fixed by methanol 21 hr after trans-
fection for 10 min, Giemsa stained for 2 hr, and decolorized with 95% ethanol.
Nuclei inside syncytia were counted under light microscopy. Syncytia were
defined as four or more nuclei within a common cell membrane. Relative
fusion was defined by normalizing the number of nuclei per syncytia formed
under the experimental conditions to that formed by in vehicle (ethanol) treated
cells, which was set at 100%. Liposome competition assay are described in
detail in Supplemental Experimental Procedures.
HIV Infection in NRG-hu Mice
NOD-Rag1nullIl2rgnull (NRG-hu) mice with stable human leukocyte reconstitu-
tion were administered 25HC (50 mg/kg) or the vehicle control (HbCD) by i.p.
injection for 12 hr before infection with HIV NL4-R3A (5 ng of p24/mouse) or
mock supernatant by intravenous injection (i.v.). Mice were administered
equal amount of 25HC or HbCD every day. HIV replication (genome copy/
ml in the plasma) was measured by qRT-PCR or by p24 intracellular staining
(Supplemental Experimental Procedures). All animals were housed and
treated in accordance with protocols approved by the institutional care
and use committee for animal research at the University of North Carolina.
Mouse Infections and Bioluminescence Imaging
C57BL/6 and Ch25h/ mice were purchased from Jackson Labs. MHV68
(500 pfu) in 200 mL of PBS was administered by i.p. After 3 dpi, mice were
imaged every day (IVIS, Xenogen) (Supplemental Experimental Procedures).
At 9 dpi, mice were euthanized and the spleens were extracted and homoge-
nized in DMEM. Total DNA was extracted using DNeasy Blood & Tissue Kit
(QIAGEN) and MHV68 DNA was quantified by qRT-PCR. All animals were
housed and treated in accordance with protocols approved by the Institutional
Care and Animal Research Committed at UCLA.
Statistics
For comparison of different experimental conditions at one time point,
student’s t test with unpaired, two-tailed hypothesis was used. For kinetic
assays, two-way ANOVA with repeated measures was used.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures and Supplemental Experi-
mental Procedures and can be found with this article online at http://dx.doi.
org/10.1016/j.immuni.2012.11.005.
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